| Literature DB >> 25216083 |
Tiantao Zhang1, Mingxia He2, Angharad M R Gatehouse3, Zhenying Wang4, Martin G Edwards5, Qing Li6, Kanglai He7.
Abstract
Two colonies of Asian corn borer, Ostrinia furnacalis (Guenée), artificially selected from a Bt-susceptible colony (ACB-BtS) for resistance to Cry1Ab (ACB-AbR) and Cry1Ac (ACB-AcR) toxins, were used to analyze inheritance patterns of resistance to Cry1 toxins. ACB-AbR and ACB-AcR evolved significant levels of resistance, with resistance ratios (RR) of 39-fold and 78.8-fold to Cry1Ab and Cry1Ac, respectively. The susceptibility of ACB-AbR larvae to Cry1Ac and Cry1F toxins, which had not previously been exposed, were significantly reduced, being >113-fold and 48-fold, respectively. Similarly, susceptibility of ACB-AcR larvae to Cry1Ab and Cry1F were also significantly reduced (RR > nine-fold, RR > 18-fold, respectively), indicating cross-resistance among Cry1Ab, Cry1Ac, and Cry1F toxins. However, ACB-AbR and ACB-AcR larvae were equally susceptible to Cry1Ie as were ACB-BtS larvae, indicating no cross-resistance between Cry1Ie and Cry1Ab or Cry1Ac toxins; this may provide considerable benefits in preventing or delaying the evolution of resistance in ACB to Cry1Ab and Cry1Ac toxins. Backcrossing studies indicated that resistance to Cry1Ab toxin was polygenic in ACB-AbR, but monogenic in ACB-AcR, whilst resistance to Cry1Ac toxin was primarily monogenic in both ACB-AbR and ACB-AcR, but polygenic as resistance increased.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25216083 PMCID: PMC4179155 DOI: 10.3390/toxins6092694
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Susceptibility of Cry1Ab-selected (ACB-AbR, R) and susceptible (ACB-BtS, S) strains of O. furnacalis and their F1 progenies of reciprocal crosses to 4 Bt toxins.
| Bt toxins | Colony | LC50 (95%FL) μg/g | Resistance ratio RR50 | χ2 | Slope ± SE |
|---|---|---|---|---|---|
| Cry1Ab | ACB-BtS | 0.12 (0.05–0.21) | - | 8.19 | 1.05 ± 0.11 |
| ACB-AbR | 4.73 (2.67–8.07) | 39.42 | 19.91 | 1.0 ± 0.06 | |
| F1 (S×R) | 1.40 (0.86–2.36) | 11.67 | 6.78 | 0.85 ± 0.08 | |
| F1 (R×S) | 2.01 (1.25–3.34) | 16.75 | 2.19 | 0.77 ± 0.07 | |
| Cry1Ac | ACB-BtS | 0.10 (0.07–0.15) | - | 8.44 | 1.05 ± 0.06 |
| ACB-AbR | 11.34 (6.88–23.77) | 113.40 | 3.34 | 0.86 ± 0.24 | |
| F1 (S×R) | 1.29 (0.88–1.89) | 12.90 | 9.03 | 0.89 ± 0.08 | |
| F1 (R×S) | 1.82 (1.12–3.05) | 18.20 | 5.52 | 0.82 ± 0.07 | |
| Cry1F | ACB-BtS | 0.64 (0.46–1.05) | - | 3.60 | 0.90 ± 0.09 |
| ACB-AbR | 31.20 (17.98–114.40) | 48.75 | 12.10 | 0.88 ± 0.19 | |
| F1 (S×R) | 1.99 (1.24–3.31) | 3.11 | 5.78 | 0.81 ± 0.07 | |
| F1 (R×S) | 2.97 (1.87–4.95) | 4.64 | 4.08 | 0.70 ± 0.07 | |
| Cry1Ie | ACB-BtS | 1.36 (0.54–2.83) | - | 15.77 | 1.80 ± 0.13 |
| ACB-AbR | 1.95 (1.23–3.14) | 1.60 | 12.20 | 1.08 ± 0.10 | |
| F1 (S×R) | 1.00 (0.58–1.76) | 0.74 | 7.09 | 0.90 ± 0.08 | |
| F1 (R×S) | 1.10 (0.74–1.64) | 0.81 | 3.50 | 0.87 ± 0.08 |
Susceptibility of ACB-AcR and ACB-BtS strains and their F1 progenies from reciprocal crosses to four Bt toxins.
| Bt Toxins | Colony | LC50 (95% FL) μg/g | Resistance Ratio RR50 | χ2 | Slope ± SE |
|---|---|---|---|---|---|
| Cry1Ab | ACB-BtS | 0.12 (0.05–0.21) | - | 8.19 | 1.05 ± 0.11 |
| ACB-AcR | 1.17 (0.65–1.96) | 9.75 | 18.85 | 0.95 ± 0.06 | |
| S×R | 1.20 (0.82–1.74) | 10.00 | 4.70 | 0.94 ± 0.08 | |
| R×S | 1.51 (1.03–2.23) | 12.58 | 3.16 | 0.91 ± 0.08 | |
| Cry1Ac | ACB-BtS | 0.10 (0.07–0.15) | - | 8.44 | 1.05 ± 0.06 |
| ACB-AcR | 7.88 (3.59–18.61) | 78.80 | 28.94 | 0.79 ± 0.06 | |
| S×R | 1.28 (0.89–1.84) | 12.80 | 4.89 | 1.99 ± 0.08 | |
| R×S | 2.63 (1.71–4.19) | 26.30 | 3.11 | 0.76 ± 0.07 | |
| Cry1F | ACB-BtS | 0.64 (0.46–1.05) | - | 3.60 | 0.90 ± 0.09 |
| ACB-AcR | 11.61 (6.70–23.28) | 18.14 | 8.54 | 0.61 ± 0.05 | |
| S×R | 2.70 (1.57–5.09) | 4.22 | 6.72 | 0.84 ± 0.08 | |
| R×S | 4.76 (2.45–10.70) | 7.44 | 8.39 | 0.75 ± 0.07 | |
| Cry1Ie | ACB-BtS | 1.36 (0.54–2.83) | - | 15.77 | 1.8 ± 0.13 |
| ACB-AcR | 1.88 (0.98–3.42) | 1.38 | 23.60 | 0.96 ± 0.06 | |
| S×R | 1.34 (0.73–2.44) | 0.99 | 9.80 | 0.98 ± 0.08 | |
| R×S | 1.73 (1.11–2.77) | 1.27 | 5.96 | 0.92 ± 0.08 |
Estimation of dominance for F1 progenies of reciprocal crosses between ACB-AbR and ACB-BtS or ACB-AcR and ACB-BtS.
| Toxin | Concentration (µg/g) | ||||
|---|---|---|---|---|---|
| ACB-AbRS | ACB-SAbR | ACB-AcRS | ACB-SAcR | ||
| Cry1Ab | 0.10 | 1.00 | 1.00 | 1.00 | 1.00 |
| 1.00 | 0.90 | 0.78 | 1.00 | 1.00 | |
| 10.00 | 0.44 | 0.35 | 0.80 | 0.74 | |
| Cry1Ac | 0.10 | 1.00 | 1.00 | 1.00 | 1.00 |
| 1.00 | 0.98 | 0.79 | 0.83 | 0.67 | |
| 10.00 | 0.52 | 0.20 | 0.43 | 0.20 | |
| Cry1F | 0.10 | 1.00 | 1.00 | 1.00 | 1.00 |
| 1.00 | 0.90 | 0.80 | 0.70 | 1.00 | |
| 10.00 | 0.60 | 0.40 | 0.40 | 0.50 | |
| 100.00 | 0.30 | 0.10 | 0.15 | 0.06 | |
Susceptibility of ACB-AbR and ACB-AcR strains and their progenies of reciprocal crosses toward four Bt toxins.
| Toxins | Colony | LC50 (95% FL) µg/g | Resistance ratio | χ2 | Slope ± SE |
|---|---|---|---|---|---|
| Cry1Ab | ACB-AbR | 4.73 (2.67–8.07) | 39.42 | 19.91 | 1.00 ± 0.06 |
| ACB-AcR | 1.17 (0.65–1.96) | 9.75 | 18.85 | 0.95 ± 0.06 | |
| ACB-AbcR | 2.85 (1.96–4.01) | 23.75 | 11.87 | 1.30 ± 0.08 | |
| ACB-AcbR | 1.55 (0.93–2.43) | 12.92 | 18.80 | 1.24 ± 0.07 | |
| Cry1Ac | ACB-AbR | 11.34 (6.88–23.77) | 113.40 | 3.34 | 0.86 ± 0.24 |
| ACB-AcR | 7.88 (3.59–18.61) | 78.80 | 28.94 | 0.79 ± 0.06 | |
| ACB-AbcR | 10.25 (7.94–13.35) | 102.50 | 5.14 | 0.88 ± 0.06 | |
| ACB-AcbR | 19.81 (15.41–25.87) | 198.10 | 3.90 | 0.99 ± 0.08 | |
| Cry1F | ACB-AbR | 31.20 (17.98–114.40) | 48.75 | 12.10 | 0.88 ± 0.19 |
| ACB-AcR | 11.61 (6.70–23.28) | 18.14 | 8.54 | 0.61 ± 0.05 | |
| ACB-AbcR | 35.80 (22.00–67.61) | 55.94 | 1.24 | 0.59 ± 0.06 | |
| ACB-AcbR | 47.78 (29.56–91.45) | 74.66 | 4.13 | 0.66 ± 0.07 | |
| Cry1Ie | ACB-AbR | 1.95 (1.23–3.14) | 1.60 | 12.20 | 1.08 ± 0.10 |
| ACB-AcR | 1.88 (0.98–3.42) | 1.38 | 23.60 | 0.96 ± 0.06 | |
| ACB-AbcR | 1.66 (1.00–2.57) | 1.22 | 16.69 | 1.16 ± 0.08 | |
| ACB-AcbR | 1.12 (0.61–1.94) | 0.82 | 21.65 | 0.99 ± 0.06 |
Indirect tests for deviation between observed and expected mortality for monogenic and additive polygenic models in ACB-AbR and ACB-AcR to Cry1Ab.
| Strains | Concentration (µg/g) | |||||||
|---|---|---|---|---|---|---|---|---|
| 0.05 | 0.25 | 0.50 | 2.50 | 5.00 | 25.00 | 50.00 | ||
| ACB-AbRS×ACBAbR | Actual mortality (%) | 18.06 | 27.08 | 41.67 | 70.14 | 78.47 | 93.75 | 97.22 |
| Expected mortality (%) | 11.63 | 16.03 | 23.09 | 42.71 | 53.47 | 73.44 | 85.59 | |
| χ2 | 5.78 | 13.06 | 27.98 | 44.28 | 36.17 | 30.46 | 15.80 | |
| 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Mean difference (%) | 17.20 | |||||||
| ACB-AcRS×ACB-BtS | Actual mortality (%) | 21.53 | 40.97 | 48.61 | 79.17 | 86.11 | 95.14 | 97.92 |
| Expected mortality (%) | 14.49 | 21.70 | 32.46 | 49.13 | 64.97 | 87.67 | 93.23 | |
| χ2 | 1.21 | 2.92 | 3.26 | 2.70 | 1.82 | 0.83 | 1.00 | |
| 0.27 | 0.09 | 0.07 | 0.10 | 0.18 | 0.36 | 0.32 | ||
| Mean difference (%) | 4.64 | |||||||
Indirect tests for deviation between observed and expected mortality for monogenic and additive polygenic models in ACB-AbR and ACB-AcR to Cry1Ac.
| Strains | Concentration (µg/g) | |||||||
|---|---|---|---|---|---|---|---|---|
| 0.05 | 0.25 | 0.50 | 2.50 | 5.00 | 25.00 | 50.00 | ||
| ACB-AbRS×ACB-AbR | Actual mortality (%) | 17.36 | 21.53 | 28.47 | 43.06 | 59.72 | 77.78 | 94.44 |
| Expected mortality (%) | 19.30 | 24.10 | 28.82 | 41.15 | 51.22 | 69.79 | 83.16 | |
| χ2 | 0.35 | 0.52 | 0.01 | 0.22 | 4.17 | 4.36 | 13.09 | |
| 0.56 | 0.47 | 0.93 | 0.64 | 0.04 | 0.04 | 0.00 | ||
| Mean difference (%) | 4.93 | |||||||
| ACB-AcRS×ACB-BtS | Actual mortality (%) | 20.83 | 40.28 | 49.31 | 72.22 | 83.33 | 90.97 | 95.14 |
| Expected mortality (%) | 10.42 | 16.27 | 21.98 | 38.54 | 48.09 | 68.89 | 80.21 | |
| χ2 | 1.52 | 0.93 | 1.09 | 7.72 | 4.78 | 6.67 | 5.78 | |
| 0.22 | 0.34 | 0.30 | 0.01 | 0.03 | 0.01 | 0.02 | ||
| Mean difference (%) | 3.89 | |||||||